Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLCPresented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMODosed first patient in U.S.
Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce important updates to its partnership
New York, New York--(Newsfile Corp. - October 28, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ:AVBP)
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major
44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN
First-in-human data for ARR-217 selected as a late-breaking oral presentation ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa.,
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ:AVBP) investors concerning the Company’s and/or members of
NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ:AVBP). The
ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is
NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Shares of ArriVent BioPharma (NASDAQ:AVBP) fell as much as 63% on October 6, 2026, sinking to a 52-week low near $12.09, after the Company announced that its global Phase 3
NEW YORK CITY, NY / ACCESS Newswire / October 8, 2026 / Shareholders of ArriVent BioPharma (NASDAQ:AVBP) saw between 50% and 63% of their investment's value disappear today, October 6, 2026, after the Company
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ArriVent BioPharma, Inc. ("ArriVent" or
AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities
